Pair Name	Gambogenic acid, Erlotinib
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	FRS2	hsa10818
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	RPS6	hsa6194
	Down-regulation	Phosphorylation	FGFR3	hsa2261
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	EGFR	hsa1956
In Vitro Model	HCC827	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_2063
	HCC827 ER1	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_EJ07
	NCI-H1650	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1483
In Vivo Model	The human cell-derived tumor xenografts (CDX) were established by s.c. injecting 0.2 ml of the tumor cell suspension (1×10⁷ cells) mixed 1:1 with Matrigel (Becton Dickinson).
Result	Our findings provide preclinical evidence for using GNA as an FGFR signaling pathway inhibitor to overcome erlotinib resistance in NSCLC treatment or to enhance erlotinib efficacy when used as a combined administration.